-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FvuBszE+nT5LbC+c8GovTc+uheNRCNe8REQwQFvicknB4ot6nO5NdnMmHRiXqved
 UC92d0alMBTmxDIiF1iWLg==

<SEC-DOCUMENT>0001127855-08-000183.txt : 20080523
<SEC-HEADER>0001127855-08-000183.hdr.sgml : 20080523
<ACCEPTANCE-DATETIME>20080523145033
ACCESSION NUMBER:		0001127855-08-000183
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080521
FILED AS OF DATE:		20080523
DATE AS OF CHANGE:		20080523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SINOVAC BIOTECH LTD
		CENTRAL INDEX KEY:			0001084201
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			B9
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32371
		FILM NUMBER:		08857895

	BUSINESS ADDRESS:	
		STREET 1:		39 SHANGDI XI ROAD
		STREET 2:		HAIDIAN DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100085
		BUSINESS PHONE:		86-10-82890088

	MAIL ADDRESS:	
		STREET 1:		39 SHANGDI XI ROAD
		STREET 2:		HAIDIAN DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NET FORCE SYSTEMS INC
		DATE OF NAME CHANGE:	19991110
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sinovac6k052108.htm
<DESCRIPTION>SINOVAC BIOTECH 6K, 05.21.08
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">

<html>

	<head>
		<title>Untitled Page</title>
	</head>

	<body bgcolor="#ffffff">
		<br>
		<br>
		<br>
		<div align="center">
			<p>FORM 6-K<br>
				<br>
				SECURITIES AND EXCHANGE COMMISSION<br>
				Washington D.C. 20549<br>
				<br>
				REPORT OF FOREIGN ISSUER<br>
				PURSUANT TO RULE 13a-16 OR 15d-16 OF THE<br>
				SECURITIES EXCHANGE ACT OF 1934<br>
				<br>
				For the month of May 2008<br>
				__________<br>
				<br>
				Commission File Number: 001-32371<br>
				__________<br>
				<br>
				SINOVAC BIOTECH LTD.<br>
				<br>
				39 Shangdi Xi Road<br>
				Haidian District<br>
				Beijing 100085, People&rsquo;s Republic of China<br>
				(Address of principal executive offices)<br>
				<br>
				<br>
			</p>
		</div>
		<div align="left">
			<p>Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.<br>
			</p>
		</div>
		<div align="center">
			<p>Form 20-F&nbsp;&nbsp;&nbsp;&nbsp; ___<u>X</u>____&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; _________<br>
				<br>
			</p>
		</div>
		<div align="left">
			<p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):________________<br>
				<br>
				Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):________________<br>
				<br>
				Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.<br>
			</p>
		</div>
		<div align="center">
			<p>Yes&nbsp; ________&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;No&nbsp;&nbsp; ___<u>X</u>____<br>
			</p>
		</div>
		<div align="left">
			<p>If &quot;Yes&quot; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):<br>
			</p>
		</div>
		<div align="center">
			<p>82-&nbsp; ____<u>N/A</u>____</p>
		</div>
		<br>
		<br>
		<br>
		<br>
		<br>
		<hr>
		<H5 align="left" style="page-break-before:always">&nbsp;</H5>
		<div align="center">
			<p>SINOVAC BIOTECH LTD.<br>
				<br>
				Form 6-K<br>
				<br>
				TABLE OF CONTENTS<br>
				<br>
			</p>
		</div>
		<div align="left">
			<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Page<br>
					<br>
				</u>Signature&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3<br>
				Exhibit 99.1 &#150; Press Release&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
			</p>
		</div>
		<hr>
		<H5 align="left" style="page-break-before:always">&nbsp;</H5>
		<br>
		<div align="center">
			<p>SIGNATURE<br>
				<br>
			</p>
		</div>
		<div align="left">
			<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br>
				<br>
				<br>
				&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SINOVAC BIOTECH LTD.<br>
				<br>
				<br>
				&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By:&nbsp; &nbsp;&nbsp;<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;/s/ Weidong Yin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
				</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: &nbsp;Weidong Yin<br>
				&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp;&nbsp; &nbsp;&nbsp;Chief Executive Officer, President<br>
				<br>
				<br>
				Date: &nbsp;May 19, 2008<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
			</p>
		</div>
		<hr>
	</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sinovacexh99_1.htm
<DESCRIPTION>SINOVAC BIOTECH 6K, PRESS RELEASE, 05.21.08
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">

<html>

	<head>
		<title>Untitled Page</title>
	</head>

	<body bgcolor="#ffffff">
		<p><br>
			<br>
		</p>
		<div align="right">
			<p><u>Exhibit 99.1<br>
					<br>
				</u></p>
		</div>
		<div align="left">
			<p><font size="+1">Sinovac Provides Support to China's Ministry of Health to Aid Earthquake Victims<br>
				</font><br>
				Wednesday May 21, 2:00 pm ET<br>
				<br>
				BEIJING, May 21 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that it is providing immediate support to China's Ministry of Health following the May 12th earthquake in Sichuan province. The assistance is intended to support disease control efforts and includes 50,000 doses of Healive&reg;, Sinovac's internally developed and commercialized hepatitis A vaccine, as well as RMB 500,000 and the expertise of Sinovac's disease control experts. In addition, Sinovac's employees contributed RMB 110,000 for the Ministry of Health's disease control initiatives.<br>
				<br>
				The Healive supply will be applied to the disaster zone, where the water supply infrastructure has been badly damaged. According to the WHO, hepatitis A is associated with inadequate water supplies and poor sanitation and hygiene, leading to infection and inflammation of the liver. Sinovac believes, because of economies of scale achieved in its Healive manufacturing process, that it can easily make this donation while still being able to meet any additional demand.<br>
				<br>
				Mr. Weidong Yin, Chairman, President and CEO, stated, &quot;While many Chinese companies and citizens are mobilizing to aid the victims of the May 12th earthquake, Sinovac is proud to provide assistance, vaccine donations and financial resources for disease control. Our close coordination with the Ministry of Health on this undertaking underscores our team's extensive scientific and field knowledge about disease prevention and their ability to provide advisory services to raise awareness about disease prevention and the benefits of vaccine administration.&quot;<br>
				<br>
				About Sinovac<br>
				<br>
				Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive&reg; (hepatitis A), Bilive&reg; (combined hepatitis A and B), Anflu&reg; (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com .<br>
				<br>
				<br>
				<br>
			</p>
		</div>
		<hr>
		<H5 align="left" style="page-break-before:always">&nbsp;</H5>
		&nbsp;&nbsp;&nbsp; For more information, please contact:<br>
		<br>
		&nbsp;&nbsp;&nbsp; Helen G. Yang<br>
		&nbsp;&nbsp;&nbsp;&nbsp; Sinovac Biotech Ltd.<br>
		&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp;&nbsp; +86-10-8289-0088 Ext. 871<br>
		&nbsp;&nbsp;&nbsp;&nbsp; Fax:&nbsp;&nbsp; +86-10-6296-6910<br>
		&nbsp;&nbsp;&nbsp;&nbsp; Email: info@sinovac.com<br>
		<br>
		&nbsp;&nbsp;&nbsp; Investors/Media:<br>
		&nbsp;&nbsp;&nbsp;&nbsp; Stephanie Carrington/Janine McCargo<br>
		&nbsp;&nbsp;&nbsp;&nbsp; The Ruth Group<br>
		&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp;&nbsp; 646-536-7017/7033<br>
		&nbsp;&nbsp;&nbsp;&nbsp; Email: scarrington@theruthgroup.com<br>
		&nbsp;&nbsp;&nbsp;&nbsp; Email: jmccargo@theruthgroup.com<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<hr>
	</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
